Copy to clipboard 
Medacta reported orthopedic sales of EUR 288.6 million (USD $311.7 million) in 1H24, up 13.1% from the first half of 2023.
The company saw strength across products and regions. The EMEA region provided healthy growth in every country with contributions from both existing accounts and new customers. Medacta cited the “remarkable performance” of both the knee and shoulder businesses in North America.
Medacta’s NextAR system supported growth in both shoulders and spine. Sales force expansion, supply chain investment and the new GMK SpheriKA knee provided additional momentum.
“This is a special year for Medacta,” said CEO Francesco Siccardi. “We are celebrating our 25th anniversary with a world tour featuring a series of scientific events, underscoring our commitment to sustainable innovation aimed at enhancing care, outcomes and patient well-being. The excellent performance recorded this semester is even more relevant if we consider the extraordinary growth reached in 1H 2023. This result confirms, once again, our ability to continuously outperform the orthopedic market.”
Medacta’s focus on innovation and sustainability created a strong track record. The company has significantly outperformed the overall market and its target segments.
Since 2019, Medcata has an 8.4% CAGR for hip replacement and 16.3% for knee replacement. Its total sales CAGR for that period is 13.7%, about four times the orthopedic market’s historical growth rate.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1H24 | 1H23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $280.6 | $247.3 | $33.3 | 13.5% |
| Knees | $125.4 | $106.4 | $19.0 | 17.9% |
| Hips | $130.9 | $123.2 | $7.7 | 6.3% |
| Extremities | $24.3 | $17.7 | $6.6 | 37% |
| Spine | $25.3 | $23.6 | $1.7 | 7.2% |
| Sports Medicine | $1.8 | $1.1 | $0.7 | 69% |
| Enabling Technology | $4.0 | $3.6 | $0.4 | 10.7% |
| Total | $311.7 | $275.6 | $36.1 | 13.1% |
Orthopedic Sales by Geography
| Region | 1H24 | 1H23 | $ Chg | % Chg |
|---|---|---|---|---|
| Americas | $97.3 | $87.1 | $10.2 | 11.7% |
| North America | $91.7 | $82.6 | $9.1 | 11% |
| South America | $5.6 | $4.6 | $1.1 | 23.2% |
| OUS | $214.4 | $188.4 | $26.0 | 13.8% |
| EMEA | $155.7 | $132.9 | $22.8 | 17.2% |
| APAC | $58.6 | $55.5 | $3.1 | 5.6% |
| Total | $311.7 | $275.6 | $36.1 | 13.1% |
Medacta reported orthopedic sales of EUR 288.6 million (USD $311.7 million) in 1H24, up 13.1% from the first half of 2023.
The company saw strength across products and regions. The EMEA region provided healthy growth in every country with contributions from both existing accounts and new customers. Medacta cited the "remarkable...
Medacta reported orthopedic sales of EUR 288.6 million (USD $311.7 million) in 1H24, up 13.1% from the first half of 2023.
The company saw strength across products and regions. The EMEA region provided healthy growth in every country with contributions from both existing accounts and new customers. Medacta cited the “remarkable performance” of both the knee and shoulder businesses in North America.
Medacta’s NextAR system supported growth in both shoulders and spine. Sales force expansion, supply chain investment and the new GMK SpheriKA knee provided additional momentum.
“This is a special year for Medacta,” said CEO Francesco Siccardi. “We are celebrating our 25th anniversary with a world tour featuring a series of scientific events, underscoring our commitment to sustainable innovation aimed at enhancing care, outcomes and patient well-being. The excellent performance recorded this semester is even more relevant if we consider the extraordinary growth reached in 1H 2023. This result confirms, once again, our ability to continuously outperform the orthopedic market.”
Medacta’s focus on innovation and sustainability created a strong track record. The company has significantly outperformed the overall market and its target segments.
Since 2019, Medcata has an 8.4% CAGR for hip replacement and 16.3% for knee replacement. Its total sales CAGR for that period is 13.7%, about four times the orthopedic market’s historical growth rate.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1H24 | 1H23 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $280.6 | $247.3 | $33.3 | 13.5% |
| Knees | $125.4 | $106.4 | $19.0 | 17.9% |
| Hips | $130.9 | $123.2 | $7.7 | 6.3% |
| Extremities | $24.3 | $17.7 | $6.6 | 37% |
| Spine | $25.3 | $23.6 | $1.7 | 7.2% |
| Sports Medicine | $1.8 | $1.1 | $0.7 | 69% |
| Enabling Technology | $4.0 | $3.6 | $0.4 | 10.7% |
| Total | $311.7 | $275.6 | $36.1 | 13.1% |
Orthopedic Sales by Geography
| Region | 1H24 | 1H23 | $ Chg | % Chg |
|---|---|---|---|---|
| Americas | $97.3 | $87.1 | $10.2 | 11.7% |
| North America | $91.7 | $82.6 | $9.1 | 11% |
| South America | $5.6 | $4.6 | $1.1 | 23.2% |
| OUS | $214.4 | $188.4 | $26.0 | 13.8% |
| EMEA | $155.7 | $132.9 | $22.8 | 17.2% |
| APAC | $58.6 | $55.5 | $3.1 | 5.6% |
| Total | $311.7 | $275.6 | $36.1 | 13.1% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
